Bridge Bio Committed To Novel UC Candidate Despite Phase II Efficacy Miss
Safety, Tolerability Profile Data Consistent
Executive Summary
South Korea’s Bridge Biotherapeutics aims to continue development of its first-in-class ulcerative colitis candidate BBT-401 despite its failure to meet the efficacy endpoint in a multinational Phase IIa study, and is also looking to progress other pipeline assets and out-licensing deals.